Kristin Neff
Vice President - Clinical Operations GentiBio
Seminars
Wednesday 2nd December 2026
Early-Phase Clinical Evaluation of GNTI-122, an Engineered Regulatory T-Cell Therapy, in Recent Onset Type 1 Diabetes
11:00 am
- Recruiting and retaining patients for engineered Treg cell therapy studies through targeted education of physicians, site staff, and patients
- How to operationalize execution of autologous cell therapy studies to ensure excellent quality cell collection, cell delivery, study participant management and data collection
- Update on the POLARIS Study progress
